Evidence map›Paper›PMID 25077648›Full record

ReviewGenetics in medicine : official journal of the American College of Medical Genetics2015

Delineating the 15q13.3 microdeletion phenotype: a case series and comprehensive review of the literature.

Chelsea Lowther, Gregory Costain, Dimitri J Stavropoulos, Rebecca Melvin, Candice K Silversides, Danielle M Andrade, Joyce So, Hanna Faghfoury, Anath C Lionel, Christian R Marshall and 2 more

Abstract readCase ReportsReview
In one paragraph

Review in Genetics in medicine : official journal of the American College of Medical Genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it, 189 citations in OpenAlex.

  1. Autism spectrum disorder and schizophrenia: An updated conceptual review.Autism research : official journal of the International Society for Autism Research · 2022
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Chelsea Lowther1] Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Gregory CostainClinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Dimitri J Stavropoulos1] Cytogenetics Laboratory, Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada [2] Department of Laboratory Medicine and Pathology, University of Toronto, Toronto, Ontario, Canada.
Rebecca MelvinClinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Candice K Silversides1] Division of Cardiology, Department of Medicine, University Health Network, Toronto, Ontario, Canada [2] Division of Obstetric Medicine, Medical Disorders of Pregnancy Program, Mount Sinai Hospital, Toronto, Ontario, Canada.
Danielle M Andrade1] Division of Neurology, Toronto Western Hospital, Toronto, Ontario, Canada [2] Krembil Neurosciences Centre, University of Toronto, Toronto, Ontario, Canada.
Joyce So1] Department of Laboratory Medicine and Pathology, University of Toronto, Toronto, Ontario, Canada [2] Department of Clinical Genetics, Lakeridge Health Oshawa, Oshawa, Ontario, Canada.
Hanna FaghfouryThe Fred A. Litwin and Family Centre in Genetic Medicine, University Health Network and Mount Sinai Hospital, Toronto, Ontario, Canada.
Anath C Lionel1] The Centre for Applied Genomics and Program in Genomics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada [2] Department of Molecular Genetics and McLaughlin Centre, University of Toronto, Toronto, Ontario, Canada.
Christian R Marshall1] The Centre for Applied Genomics and Program in Genomics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada [2] Department of Molecular Genetics and McLaughlin Centre, University of Toronto, Toronto, Ontario, Canada.
Stephen W Scherer1] Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada [2] The Centre for Applied Genomics and Program in Genomics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada [3] Department of Molecular Genetics and McLaughlin Centre, University of Toronto, Toronto, Ontario, Canada.
Anne S Bassett1] Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada [3] Division of Cardiology, Department of Medicine, University Health Network, Toronto, Ontario, Canada [4] Department of Psychiatry, University of Toronto and University Health Network, Toronto, Ontario, Canada.
Centre for Addiction and Mental Health · CAHospital for Sick Children · CAMount Sinai Hospital · CALakeridge Health · CAOntario Genomics · CAToronto Western Hospital · CAUniversity of Toronto · CA

Funding

CIHR 107520-1CIHR MOP 111238CIHR MOP 89066
6 · The paper itself

Abstract

purposeRecurrent 15q13.3 deletions are enriched in multiple neurodevelopmental conditions including intellectual disability, autism, epilepsy, and schizophrenia. However, the 15q13.3 microdeletion syndrome remains ill-defined.

methodsWe systematically compiled all cases of 15q13.3 deletion published before 2014. We also examined three locally available cohorts to identify new adults with 15q13.3 deletions.

resultsWe identified a total of 246 cases (133 children, 113 adults) with deletions overlapping or within the 15q13.3 (breakpoint (BP)4-BP5) region, including seven novel adult cases from local cohorts. No BP4-BP5 deletions were identified in 23,838 adult controls. Where known, 15q13.3 deletions were typically inherited (85.4%) and disproportionately of maternal origin (P < 0.0001). Overall, 198 cases (121 children, 77 adults; 80.5%) had at least one neuropsychiatric diagnosis. Accounting for ascertainment, developmental disability/intellectual disability was present in 57.7%, epilepsy/seizures in 28.0%, speech problems in 15.9%, autism spectrum disorder in 10.9%, schizophrenia in 10.2%, mood disorder in 10.2%, and attention deficit hyperactivity disorder in 6.5%. By contrast, major congenital malformations, including congenital heart disease (2.4%), were uncommon. Placenta previa occurred in the pregnancies of four cases.

conclusionThe 15q13.3 microdeletion syndrome is predominantly characterized by neuropsychiatric expression. There are implications for pre- and postnatal detection, genetic counseling, and anticipatory care.

Indexed as

PhenotypeAdultAgedChromosome BreakpointsChromosome DeletionChromosome DisordersChromosomes, Human, Pair 15Cohort StudiesFemaleGenetic Association StudiesHomozygoteHumansInheritance PatternsIntellectual DisabilityMaleMiddle Aged

Identifiers

PMID25077648
PMCPMC4464824
OpenAlexW1993890839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.